Enoxaparin (Clexane, Clexiwin)
Enoxaparin
Sanofi-aventis South Africa (Pty) Ltd
Registration
- Applicant
- Sanofi-aventis South Africa (Pty) Ltd
- Certificate holder
- Sanofi-aventis
- Registrations
- 11
- Schedule source
- SAHPRA documentation
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Clexane 60 EACH 0,6 ml SOLUTION CONTAINS ENOXAPARIN SODIUM 60,0 mg | 60Solution for injection | 31048031/8.2/0480Approved 13 October 2023 | Registered | S4 | PIPIL |
| Clexane 80 EACH 0,8 ml SOLUTION CONTAINS:ENOXAPARIN SODIUM 80,0 mg | 80Solution for injection | 31048131/8.2/0481Approved 13 October 2023 | Registered | S4 | PIPIL |
| Clexane 100 EACH 1,0 ml SOLUTION CONTAINS:ENOXAPARIN SODIUM 100,0 mg | 100Solution for injection | 31048231/8.2/0482Approved 13 October 2023 | Registered | S4 | PIPIL |
| Clexane 300 EACH 3,0 ml SOLUTION CONTAINS:ENOXAPARIN SODIUM 300,0 mg | 300Solution for injection | 32012232/8.2/0122Approved 13 October 2023 | Registered | S4 | PIPIL |
| Clexiwin 20 EACH 0,2 ml SOLUTION CONTAINS ENOXAPARIN SODIUM 20,0 mg | 20 | 42019342/8.2/0193 | Cancelled | S4 | None |
| Clexiwin 40 EACH 0,4 ml SOLUTION CONTAINS ENOXAPARIN SODIUM 40,0 mg | 40 | 42019442/8.2/0194 | Cancelled | S4 | None |
| Clexiwin 60 EACH 0,6 ml SOLUTION CONTAINS ENOXAPARIN SODIUM 60,0 mg | 60 | 42019542/8.2/0195 | Cancelled | S4 | None |
| Clexiwin 80 EACH 0,6 ml SOLUTION CONTAINS ENOXAPARIN SODIUM 80,0 mg | 80 | 42019642/8.2/0196 | Cancelled | S4 | None |
| Clexiwin 300 EACH 3,0 ml SOLUTION CONTAINS ENOXAPARIN SODIUM 300,0 mg | 300 | 42019842/8.2/0198 | Cancelled | S4 | None |
| Clexane 20 EACH 0,2 ml SOLUTION CONTAINS: ENOXAPARIN SODIUM 20,0 mg | 20Solution for injection | A390079A39/8.2/0079Approved 13 October 2023 | Registered | S4 | PIPIL |
| Clexane 40 EACH 0,4 ml SOLUTION CONTAINS ENOXAPARIN 40 mg | 40Solution for injection | X0042X/8.2/42Approved 13 October 2023 | Registered | S4 | PIPIL |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Enoxaparin sodium
S4: Enoxaparin
Consolidated Schedules 06 July 2026, line 6186
Pharmacological class: Anticoagulants. (class 8.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
Schedule Verification
This medication's schedule (S4) has been verified from official SAHPRA documents with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.